Month: November 2017

Palatin Technologies Announces Signing of Licensing Agreement with Kwangdong Pharmaceutical for Republic of Korea

Palatin to Receive $500,000 Upfront Entitled to Receive $3.0 Million on First Commercial Sale in Korea and Up to $37.5 Million in Sales Related Milestones plus Royalties on Net Sales Nov 21, 2017, 06:30 ET CRANBURY, N.J., Nov. 21, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; “Palatin”) announced today that it has entered into …

Palatin Technologies Announces Signing of Licensing Agreement with Kwangdong Pharmaceutical for Republic of Korea Read More »

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on November 13, 2017

CRANBURY, N.J., Nov. 13, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2017.  Recent Highlights Bremelanotide – Under development for Hypoactive Sexual Desire Disorder …

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on November 13, 2017 Read More »

Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on November 13, 2017

CRANBURY, N.J., Nov. 8, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2018 operating results on Monday, November 13, 2017  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 13, …

Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on November 13, 2017 Read More »

Scroll to Top